Building a highly differentiated pipeline with first-in-class potential
First written in FY2017. 13 of 15 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-05-08.
The whole theme swung hardest in 2019: 1 of 9 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- 2026-05-08AdvancedEarnings
「There are currently 28 new drug candidates in the clinical development stage in the priority areas, of which 19 were discovered internally.」
The number of candidates in clinical development and internally discovered products increased, indicating the expansion of a highly differentiated pipeline. - FY2026-H1AdvancedAnnual report
「There are currently 24 new drug candidates in the clinical development stage in the priority areas, of which 15 were discovered internally. We are also strengthening translational research, which bridges basic and clinical research, to further improve the speed and probability of success in drug discovery.」
The number of candidates in the clinical development stage in priority areas increased from the previous 14 to 24, including 15 internally discovered candidates. - FY2025AdvancedAnnual report
「In priority areas, 14 new drug candidates, including 3 from Deciphera, have currently moved into the clinical stage.」
There are 14 clinical-stage candidates in priority areas, including 3 candidates originating from Deciphera. - FY2025-H1AdvancedAnnual report
「There are currently 14 new drug candidates in the clinical stage in the priority areas, of which 2 are from Deciphera. To further improve the speed and probability of success in drug discovery, we are also strengthening translational research bridging basic and clinical research.」
The number of clinical-stage candidates in priority areas reached 14, up from the previous 11. The expansion of the pipeline, including 2 candidates from Deciphera, is reported. - FY2024AdvancedAnnual report
「In priority areas, 11 new drug candidate compounds have currently moved into the clinical stage.」
The number of clinical-stage candidates in priority areas increased from 10 to 11, advancing the expansion of the highly differentiated pipeline. - FY2024-Q3AdvancedAnnual report
「Note 2: A Phase I trial was initiated in Japan for ONO-4538HSC, a subcutaneous formulation of ONO-4538, a combination product of nivolumab and berahyaluronidase alfa, in patients with solid tumours. Note 3: A Phase I trial was initiated in the United States for ONO-8250, an iPS cell-derived HER2 CAR-T cell therapy, in patients with HER2-positive solid tumours.」
New Phase I trials were initiated for ONO-4538HSC and ONO-8250, expanding the clinical-stage pipeline, including highly differentiated candidates. - FY2024-Q2AdvancedAnnual report
「In September this year, a Phase I trial was initiated in Japan for the PD-1×CD3 bispecific antibody ONO-4685 in patients with T-cell lymphoma. In August this year, a Phase I trial was initiated in Japan for combination therapy with the Axl/Mer inhibitor ONO-7475 and Opdivo in patients with pancreatic cancer.」
New domestic Phase I trials were initiated for a bispecific antibody and a combination therapy involving an Axl/Mer inhibitor, advancing the clinical development of highly differentiated candidates. - FY2023AdvancedAnnual report
「There are currently 10 internally discovered new drug candidate compounds in the clinical stage in the priority areas, and we are also strengthening translational research bridging basic and clinical research to further improve the speed and probability of success in drug discovery.」
The number of clinical-stage candidates in priority areas increased from 8 to 10, advancing the formation of a highly differentiated pipeline. - FY2023-Q3AdvancedAnnual report
「Note 1: The FXIa inhibitor ONO-7684 began a Phase I trial in healthy adults in Japan. Note 2: The endocannabinoid modulator ONO-1110 began a Phase I trial in healthy adults in Japan.」
Two new candidate compounds moved into the clinical stage, broadening the base of the highly differentiated development pipeline. - FY2022AdvancedAnnual report
「8 new drug candidate compounds in the priority areas have entered the clinical stage, and we are also strengthening translational research bridging basic and clinical research to further improve the speed and probability of success in drug discovery.」
The number of candidates in priority areas that have advanced to the clinical stage has reached 8 for the highly differentiated pipeline with first-in-class potential, and translational research has also been strengthened. - FY2022-Q3AdvancedAnnual report
「※5: We started a Phase III study in Japan of the anti-CD47 antibody “ONO-7913” in patients with “TP53 mutation-positive acute myeloid leukemia.” / ※6: We started Phase III studies in South Korea and Taiwan of the anti-CD47 antibody “ONO-7913” in patients with “acute myeloid leukemia.”」
The anti-CD47 antibody ONO-7913 has advanced to Phase III trials in Japan, South Korea and Taiwan, indicating that the highly differentiated development pipeline in priority areas is progressing to the late clinical stage. - FY2022-Q2AdvancedAnnual report
「Seven new drug candidate compounds in priority areas have moved into the clinical stage. To further improve the speed and probability of success in drug discovery, we will also strengthen translational research bridging basic and clinical research.」
The transition of 7 candidate compounds in priority areas to the clinical stage is cited as concrete progress in building a highly differentiated pipeline. - FY2018RestatedAnnual report
「We will designate cancer, immune diseases and central nervous system diseases as priority research areas, concentrate management resources, enhance expertise, and expand research and drug discovery partnerships with external parties, thereby strengthening a highly differentiated pipeline with first-in-class potential.」
The policy of strengthening a highly differentiated pipeline with first-in-class potential through concentration on priority areas and external partnerships has been reaffirmed. - FY2018-Q2AdvancedAnnual report
「In October this year, we entered into an agreement with Karyopharm for the exclusive development and commercialisation in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries, across all cancer types, of Selinexor, a first-in-class oral XPO1 (exportin 1) inhibitor under development by Karyopharm, and KPT-8602, a second-generation oral XPO1 inhibitor.」
An exclusive development and commercialisation agreement was entered into with Karyopharm for highly differentiated candidates with first-in-class potential, giving concrete form to the expansion of the pipeline. - FY2017First statedAnnual report
「In addition to drug discovery focused on compounds, we will designate priority research areas such as oncology, concentrate management resources, enhance expertise, and expand research and drug discovery partnerships with external parties, thereby strengthening a highly differentiated pipeline with first-in-class potential.」
This is the first statement of the goal of strengthening a highly differentiated pipeline with first-in-class potential by concentrating management resources on priority research areas, enhancing expertise and expanding external partnerships.